Sign In
Buy GOSS
$0.188
-0.0119 (-5.94%)
At Close: Jun 03, 2026
NEW YORK, May 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS). Shareholders who purchased shares of GOSS during the class p
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit
12:00am, Tuesday, 19'th May 2026
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, May 18
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit
11:55pm, Monday, 18'th May 2026
NEW YORK, May 18, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and Febru
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and Febru
Gossamer Bio, Inc. (GOSS) Q1 2026 Earnings Call Transcript
06:10pm, Monday, 18'th May 2026
Gossamer Bio, Inc. (GOSS) Q1 2026 Earnings Call Transcript
LOS ANGELES, May 18, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming June 1, 2026 deadline to file a lead plaintiff motion in the class action filed on beh
[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. (âGossamerâ or the
Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA
NEW YORK--(BUSINESS WIRE)---- $GOSS #Bio--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. (“Gossamer” or the “Company�
SAN FRANCISCO, May 18, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Monday, 18'th May 2026
New York, New York--(Newsfile Corp. - May 18, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
11:56am, Monday, 18'th May 2026
LOS ANGELES, May 18, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer�
SHAREHOLDER ALERT: Berger Montague Reminds Gossamer Bio, Inc. (GOSS) Investors of Class Action Lawsuit Deadline
09:11am, Monday, 18'th May 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - May 18, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or
Gossamer Bio Q1 Earnings Call Highlights
09:06am, Monday, 18'th May 2026
Gossamer Bio NASDAQ: GOSS said it is moving ahead with plans to seek U.S. approval for seralutinib in pulmonary arterial hypertension, outlining a September 2026 target for a New Drug Application subm
